Singapore markets closed
  • Straits Times Index

    3,270.98
    -11.90 (-0.36%)
     
  • Nikkei

    28,001.57
    -247.67 (-0.88%)
     
  • Hang Seng

    20,042.83
    -2.94 (-0.01%)
     
  • FTSE 100

    7,482.37
    +42.63 (+0.57%)
     
  • BTC-USD

    23,888.20
    +455.43 (+1.94%)
     
  • CMC Crypto 200

    557.82
    +14.94 (+2.75%)
     
  • S&P 500

    4,140.06
    -5.13 (-0.12%)
     
  • Dow

    32,832.54
    +29.07 (+0.09%)
     
  • Nasdaq

    12,644.46
    -13.10 (-0.10%)
     
  • Gold

    1,804.10
    -1.10 (-0.06%)
     
  • Crude Oil

    90.91
    +0.15 (+0.17%)
     
  • 10-Yr Bond

    2.7650
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,497.80
    +1.77 (+0.12%)
     
  • Jakarta Composite Index

    7,134.82
    +47.97 (+0.68%)
     
  • PSE Index

    6,424.61
    -9.63 (-0.15%)
     

Sage Therapeutics to Host Sage FutureCast Webcast

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., November 29, 2021--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that it will host Sage FutureCast: An R&D and Portfolio Review on Tuesday, December 14 from 8:00 a.m. to 10:00 a.m. ET.

Sage FutureCast will discuss the Company’s research and development strategy, and clinical progress in programs throughout the depression, neurology, and neuropsychiatry franchises including zuranolone, SAGE-324 and SAGE-718, respectively.

Webcast Information
A live webcast of the presentation can be accessed on the investor page of Sage's website at investor.sagerx.com.
A replay of the webcast will be available on Sage's website approximately two hours after the completion of the event and will be archived for up to 30 days.

About Sage Therapeutics
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211129005132/en/

Contacts

Investor Contact
Helen Rubinstein
315-382-3979
helen.rubinstein@sagerx.com

Media Contact
Maureen L. Suda
617-949-4289
maureen.suda@sagerx.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting